Skip to main content
Premium Trial:

Request an Annual Quote

Biocept, Prognos Partner on Biomarker-Targeted Cancer Therapies

NEW YORK (GenomeWeb) – Liquid biopsy test maker Biocept said today that it has signed a software license and laboratory data supply agreement with Prognos.

As part of the agreement, San Diego-based Biocept will provide de-identified data from its liquid biopsy testing to Prognos, which will leverage its artificial intelligence tools to help its pharmaceutical clients ensure that patients receive the right therapies. New York City-based Prognos aims to use its AI technology to drive decisions earlier in healthcare in partnership with payors, as well as life science and diagnostic companies. According to the firm, its registry is the largest source of clinical diagnostics information in 50 disease areas, with over 20 billion medical records for 185 million patients.

Biocept said it will use Prognos' Opal de-identification software in accordance with the Health Insurance Portability and Accountability Act of 1996 to collect and transmit the data to Prognos.

"The number of biomarker-targeted therapies in oncology is growing to a significant rate and new technologies like liquid biopsy offer significant potential to improve cancer care," Prognos Cofounder and CEO Sundeep Bhan said in a statement. "There is strong demand for clinical information that elucidates the capability of this innovative technology in the healthcare market."

Additional terms of the agreement were not disclosed.

With over 16,000 patient samples and 50,000 total Target Selector tests performed, Biocept said that it is positioned to continue generating clinical data that — once anonymized and aggregated — can be used by the scientific, medical, and healthcare delivery sectors.